We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
PLSE Shares Rise on First-in-Human Data for Thyroid Nodule Treatment
Read MoreHide Full Article
Key Takeaways
Pulse Biosciences published the first-in-human study on nsPFA for benign thyroid nodules.
The study showed up to 93% reduction in nodule size with early symptom relief.
Shares rose 2.6% after results highlighted the safety and efficacy of nsPFA treatment.
Pulse Biosciences (PLSE - Free Report) has announced the publication of its first-in-human clinical feasibility study in the Journal Thyroid, highlighting the effectiveness of its proprietary Nanosecond Pulsed Field Ablation (nsPFA) technology for treating benign thyroid nodules. The study, conducted in Naples, Italy, showed strong outcomes in both safety and efficacy, with meaningful reductions in nodule size and symptom relief.
The publication underscores nsPFA’s potential to emerge as a differentiated treatment option for patients with benign thyroid nodules. With its nonthermal mechanism and favorable safety profile, the technology positions Pulse Biosciences to advance a promising alternative to current standard-of-care approaches.
Likely Trend of PLSE Stock Following the News
Following the announcement, the company's shares gained 2.6% at yesterday’s market closing. Shares of the company have lost 2.9% in the year-to-date period compared with the industry’s 8.6% decline. The S&P 500 has gained 9.4% in the same time frame.
This publication strengthens Pulse Biosciences’ long-term business prospects by positioning nsPFA as a disruptive alternative in the large benign thyroid nodule market, where current treatments are either invasive or less effective. Demonstrating strong safety and efficacy not only supports potential adoption by clinicians but also broadens the platform’s applicability across therapeutic areas, creating opportunities for regulatory expansion, partnerships, and recurring revenue growth.
PLSE currently has a market capitalization of $1.11 billion.
Image Source: Zacks Investment Research
More on PLSE’s Study Data
The first-in-human feasibility study, conducted at Ospedale del Mare in Naples, Italy, evaluated Pulse Biosciences’ nsPFA technology using the CellFX Percutaneous Electrode System under ultrasound guidance. The study was structured across three cohorts, with initial groups assessing tissue response through isolated ablations and the final group receiving full therapeutic treatment of benign thyroid nodules. The design allowed researchers to measure both the safety and effectiveness of nsPFA energy in a clinical setting.
Results demonstrated strong efficacy, with fully treated nodules showing an average 86% reduction in size at one year and reductions as high as 93%. Symptom improvement was observed early, with greater than 48% reduction noted within two weeks. Importantly, follow-up ultrasounds indicated no intranodular fibrosis or scarring, underscoring the favorable safety profile of nsPFA. These outcomes highlight the potential of the technology to deliver rapid, durable, and minimally invasive results compared to traditional approaches.
Favorable Industry Prospects for PLSE
Per a report by Grand View Research, the global thyroid ablation devices market size was valued at USD 168.4 million in 2023 and is expected to expand at a compound annual growth rate of 9.58% from 2024 to 2030.
There is an increasing demand for thyroid ablation procedures as well as devices owing to the rising prevalence of thyroid cancer and thyroid nodules.
PLSE’s Zacks Rank & Key Picks
Currently, PLSE carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space that have announced quarterly results are Medpace Holdings, Inc. (MEDP - Free Report) , West Pharmaceutical Services, Inc. (WST - Free Report) and Boston Scientific Corporation (BSX - Free Report) .
Medpace Holdings, sporting a Zacks Rank of 1 (Strong Buy), reported second-quarter 2025 EPS of $3.10, beating the Zacks Consensus Estimate by 3.3%. Revenues of $603.3 million outpaced the consensus mark by 11.5%. You can see the complete list of today’s Zacks #1 Rank stocks here.
Medpace Holdings has a long-term estimated growth rate of 11.4%. MEDP’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 13.9%.
West Pharmaceutical reported second-quarter 2025 adjusted EPS of $1.84, beating the Zacks Consensus Estimate by 21.9%. Revenues of $766.5 million surpassed the Zacks Consensus Estimate by 5.4%. It currently flaunts a Zacks Rank #1.
West Pharmaceutical has a long-term estimated growth rate of 8.5%. WST’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 16.8%.
Boston Scientific reported second-quarter 2025 adjusted EPS of 75 cents, beating the Zacks Consensus Estimate by 4.2%. Revenues of $5.06 billion surpassed the Zacks Consensus Estimate by 3.5%. It currently carries a Zacks Rank #2 (Buy).
Boston Scientific has a long-term estimated growth rate of 14%. BSX’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 8.1%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
PLSE Shares Rise on First-in-Human Data for Thyroid Nodule Treatment
Key Takeaways
Pulse Biosciences (PLSE - Free Report) has announced the publication of its first-in-human clinical feasibility study in the Journal Thyroid, highlighting the effectiveness of its proprietary Nanosecond Pulsed Field Ablation (nsPFA) technology for treating benign thyroid nodules. The study, conducted in Naples, Italy, showed strong outcomes in both safety and efficacy, with meaningful reductions in nodule size and symptom relief.
The publication underscores nsPFA’s potential to emerge as a differentiated treatment option for patients with benign thyroid nodules. With its nonthermal mechanism and favorable safety profile, the technology positions Pulse Biosciences to advance a promising alternative to current standard-of-care approaches.
Likely Trend of PLSE Stock Following the News
Following the announcement, the company's shares gained 2.6% at yesterday’s market closing. Shares of the company have lost 2.9% in the year-to-date period compared with the industry’s 8.6% decline. The S&P 500 has gained 9.4% in the same time frame.
This publication strengthens Pulse Biosciences’ long-term business prospects by positioning nsPFA as a disruptive alternative in the large benign thyroid nodule market, where current treatments are either invasive or less effective. Demonstrating strong safety and efficacy not only supports potential adoption by clinicians but also broadens the platform’s applicability across therapeutic areas, creating opportunities for regulatory expansion, partnerships, and recurring revenue growth.
PLSE currently has a market capitalization of $1.11 billion.
Image Source: Zacks Investment Research
More on PLSE’s Study Data
The first-in-human feasibility study, conducted at Ospedale del Mare in Naples, Italy, evaluated Pulse Biosciences’ nsPFA technology using the CellFX Percutaneous Electrode System under ultrasound guidance. The study was structured across three cohorts, with initial groups assessing tissue response through isolated ablations and the final group receiving full therapeutic treatment of benign thyroid nodules. The design allowed researchers to measure both the safety and effectiveness of nsPFA energy in a clinical setting.
Results demonstrated strong efficacy, with fully treated nodules showing an average 86% reduction in size at one year and reductions as high as 93%. Symptom improvement was observed early, with greater than 48% reduction noted within two weeks. Importantly, follow-up ultrasounds indicated no intranodular fibrosis or scarring, underscoring the favorable safety profile of nsPFA. These outcomes highlight the potential of the technology to deliver rapid, durable, and minimally invasive results compared to traditional approaches.
Favorable Industry Prospects for PLSE
Per a report by Grand View Research, the global thyroid ablation devices market size was valued at USD 168.4 million in 2023 and is expected to expand at a compound annual growth rate of 9.58% from 2024 to 2030.
There is an increasing demand for thyroid ablation procedures as well as devices owing to the rising prevalence of thyroid cancer and thyroid nodules.
PLSE’s Zacks Rank & Key Picks
Currently, PLSE carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space that have announced quarterly results are Medpace Holdings, Inc. (MEDP - Free Report) , West Pharmaceutical Services, Inc. (WST - Free Report) and Boston Scientific Corporation (BSX - Free Report) .
Medpace Holdings, sporting a Zacks Rank of 1 (Strong Buy), reported second-quarter 2025 EPS of $3.10, beating the Zacks Consensus Estimate by 3.3%. Revenues of $603.3 million outpaced the consensus mark by 11.5%. You can see the complete list of today’s Zacks #1 Rank stocks here.
Medpace Holdings has a long-term estimated growth rate of 11.4%. MEDP’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 13.9%.
West Pharmaceutical reported second-quarter 2025 adjusted EPS of $1.84, beating the Zacks Consensus Estimate by 21.9%. Revenues of $766.5 million surpassed the Zacks Consensus Estimate by 5.4%. It currently flaunts a Zacks Rank #1.
West Pharmaceutical has a long-term estimated growth rate of 8.5%. WST’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 16.8%.
Boston Scientific reported second-quarter 2025 adjusted EPS of 75 cents, beating the Zacks Consensus Estimate by 4.2%. Revenues of $5.06 billion surpassed the Zacks Consensus Estimate by 3.5%. It currently carries a Zacks Rank #2 (Buy).
Boston Scientific has a long-term estimated growth rate of 14%. BSX’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 8.1%.